Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Immunic Inc. buy tamam

Immunic Inc.
Start price
€7.50
25.03.20 / 50%
Target price
€25.00
04.11.21
Performance (%)
17.93%
End price
€8.85
05.11.21
Summary
This prediction ended on 05.11.21 with a price of €8.85. The BUY prediction by tamam finished with a performance of 17.93%. tamam has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Immunic Inc. - - - -
iShares Core DAX® -0.874% 5.325% 6.865% 65.211%
iShares Nasdaq 100 -0.381% 1.979% 25.696% 90.325%
iShares Nikkei 225® -1.676% 1.952% 41.443% 80.623%
iShares S&P 500 -0.655% 2.069% 21.405% 70.737%

Comments by tamam for this prediction

In the thread Immunic Inc. diskutieren
Prediction Buy
Perf. (%) 17.93%
Target price 15.000
Change
Ends at 04.11.21

Buy mit Kursziel 15,0

tamam 
0
Report Share
25.03.20
Prediction Buy
Perf. (%) 17.93%
Target price 25.000
Change
Ends at 04.11.21

Immunic (NASDAQ:IMUX) announces positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS).

tamam 
1
Report Share
03.08.20
In the thread Trading Immunic Inc.
Prediction Buy
Perf. (%) 17.93%
Target price 25.000
Change
Ends at 04.11.21

Die von tamam gewählte maximale Laufzeit wurde überschritten

tamam 
0
Report Share
05.11.21